Tourmaline Bio, Inc.
TRML
$15.10
-$0.64-4.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.73% | 74.43% | 234.03% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.62% | 97.61% | 122.40% | -- | -- |
| Operating Income | -77.62% | -97.61% | -122.40% | -- | -- |
| Income Before Tax | -72.89% | -73.80% | -87.09% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.89% | -73.80% | -87.09% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.89% | -73.80% | -87.09% | -- | -- |
| EBIT | -77.62% | -97.61% | -122.40% | -- | -- |
| EBITDA | -77.67% | -97.67% | -122.45% | -- | -- |
| EPS Basic | 85.89% | 90.58% | 90.65% | -- | -- |
| Normalized Basic EPS | 84.60% | 89.61% | 90.54% | -- | -- |
| EPS Diluted | 85.89% | 90.58% | 90.65% | -- | -- |
| Normalized Diluted EPS | 84.60% | 89.61% | 90.54% | -- | -- |
| Average Basic Shares Outstanding | 144.26% | 434.00% | 560.96% | -- | -- |
| Average Diluted Shares Outstanding | 144.26% | 434.00% | 560.96% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |